Methods for treating inflammation and autoimmune disease.
Summary
Methods for treating inflammation and autoimmune disease.
Overview
The cytokine IL-1beta plays a key role in the systemic inflammation characteristic of autoimmune diseases such as Inflammatory bowel disease, multiple sclerosis and type I diabetes. Controlling this type of inflammation has been challenging because IL-1beta also plays a vital role in responding to infectious diseases. Researchers at Cincinnati Children's have identified a novel cross-talk mechanism—independent of the immune response to invading pathogens—that can be targeted to reduce IL-1beta production during autoimmune inflammation without diminishing the immune response to foreign invaders.
Applications
Inflammation cytokine storms induced by CAR T cell therapy or Immune checkpoint therapy induced adverse events.
Autoimmune diseases like Inflammatory bowel disease, multiple sclerosis and type I diabetes
Value Proposition
Unlike other innovations in this field, this research targets a novel mechanism that reduces the production of IL-1beta, mitigating damaging inflammation without reducing antimicrobial immune response.
Market Overview
Autoimmune diseases such as Inflammatory bowel disease, Multiple Sclerosis and Type I Diabetes affect more than 3000 million people worldwide.
Global therapeutics market for autoimmune diseases was $54 billion (2021)
Inflammation is a driver of many autoimmune disease disorders
Investigator
Chandrashekhar Pasare, DVM, PhD Professor and Division Director, Division of Immunobiology
